Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cognitive Decline in Alzheimer's Disease: Limited Clinical Utility for GWAS or Polygenic Risk Scores in a Clinical Trial Setting.

Genes - 2 May 2020

Euesden Jack, Gowrisankar Sivakumar, Qu Angela Xiaoyan, Jean Pamela St, Hughes Arlene R, Pulford David J

Abstract excerpt

Introduction: Alzheimer's disease (AD) is a progressive and irreversible neurological disease. The genetics and molecular mechanisms underpinning differential cognitive decline in AD are not well understood; the genetics of AD risk have been studied far more assiduously. Materials and Methods: Two phase III clinical trials measuring cognitive decline over 48 weeks using Alzheimer's Disease Assessment...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alzheimer Disease
Share to Apolipoprotein E4

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clinical Trials as Topic

Share to Cognitive Dysfunction

Share to Disease Progression

Share to Genome-Wide Association Study

Share to Multifactorial Inheritance

Share to Neuropsychological Tests

Source

Open in PubMed Open full text

Identifiers

PMID: 32370229
DOI: 10.3390/genes11050501
PMCID: PMC7290959

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cognitive Decline in Alzheimer's Disease: Limited Clinical Utility for GWAS or Polygenic Risk Scores in a Clinical Trial Setting.PMID 32370229Read ↗

Patient stratification by genetic risk in Alzheimer's disease is only effective in the presence of phenotypic heterogeneity.Semantic proximity Read ↗

Polygenic Risk Scoring is an Effective Approach to Predict Those Individuals Most Likely to Decline Cognitively Due to Alzheimer's DiseaseSemantic proximity Read ↗

Polygenic risk scores for Alzheimer's disease in relation to cognitive change: A representative sample from the general population followed over 16 years.Semantic proximity Read ↗

Utility of an Alzheimer’s Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer’s Disease: A Prospective Longitudinal StudySemantic proximity Read ↗

Polygenic risk of Alzheimer disease is associated with early- and late-life processes.Semantic proximity Read ↗

Genetic Stratification to Identify Risk Groups for Alzheimer's Disease.Semantic proximity Read ↗

Population-specific polygenic risk for Alzheimer’s disease is associated with Mini-Mental State Examination-based cognitive decline in a Japanese cohortSemantic proximity Read ↗

A/T/N polygenic risk score for cognitive decline in old ageSemantic proximity Read ↗

Influence of Alzheimer's disease genes on cognitive decline: the Guangzhou Biobank Cohort Study.Semantic proximity Read ↗

Polygenic risk for Alzheimer's disease is not associated with cognitive ability or cognitive aging in non-demented older people.Semantic proximity Read ↗

Effect of APOE and a polygenic risk score on incident dementia and cognitive decline in a healthy older populationSemantic proximity Read ↗

Dissociable influences of APOE ε4 and polygenic risk of AD dementia on amyloid and cognition.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.